Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Final Program


CRS Abstract Guide

Industry Session

Industry Roundtable: Critical considerations, challenges, opportunities and strategies in development of once a day (QD) formulations

Wednesday, July 16, 2025
1:00 PM - 2:30 PM EDT
Location: 122 B

Sponsored By 
Once a day (QD) drug product development has gained importance due to reduced frequency of dosing and patient compliance. However, many new chemical entities in the clinical pipeline may not have the optimal properties for development of a QD formulations. Challenges of poor solubility, permeability, stability and the drug dose could be some of the critical factors that impact the product development. Selection of the optimum principle, mechanism and technology available to release the rate and extent of the drug at the target site of absorption and efficacy is key to a speedy development and proof of efficacy in human subjects is extremely important. Several critical factors and considerations related to the challenges will be discussed by the panel of experts.